文献速递基础与转化研究新药、器械与细胞基因治疗研发

囊性纤维化治疗的未来:从疾病机制到新型治疗方法

The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches.
PubMed 文献 · Lancet · 2023-09-09

本文为Lancet系列综述,聚焦2018年以来囊性纤维化(CF)治疗进展与知识缺口。高效调节剂疗法使遗传上符合条件的超过90%的CF患者获得前所未有的临床获益,CF已成为转化分子治疗的前沿。综述覆盖CFTR功能药理修复、症状治疗新策略及基因治疗与基因编辑恢复CFTR功能的潜力。

要点

  • 高效调节剂疗法使遗传上符合条件的超过90%的CF患者获得前所未有的临床获益。
  • 综述聚焦2018年以来CFTR功能障碍分子机制及其与黏液功能障碍、宿主防御受损、气道感染和慢性肺部炎症的联系。
  • 基因治疗与基因编辑有望恢复所有CF患者肺内CFTR功能,不依赖CFTR基因型。

核心结论

  • CF已成为转化分子治疗的前沿,基因治疗与基因编辑为将所有CF患者(不依赖CFTR基因型)的CFTR功能恢复带来希望,并有望将CF从致命疾病转变为可治疗甚至可能治愈的疾病。

研究设计与样本

  • Lancet系列综述,聚焦2018年以来CF治疗进展及剩余知识缺口,覆盖CFTR功能障碍分子机制、药理修复CFTR功能、症状治疗新策略及基因治疗与基因编辑。

主要发现

  • 2019年高效调节剂疗法取得突破,为遗传上符合条件的超过90%的CF患者提供前所未有的临床获益。
  • 综述讨论CFTR功能障碍分子机制与黏液功能障碍、宿主防御受损、气道感染及肺部慢性炎症的联系。
  • 综述回顾药理修复CFTR功能的进展与剩余障碍,以及改进CF症状治疗的新策略(包括可能适用于支气管扩张和慢性阻塞性肺疾病等常见肺病)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

With the 2019 breakthrough in the development of highly effective modulator therapy providing unprecedented clinical benefits for over 90% of patients with cystic fibrosis who are genetically eligible for treatment, this rare disease has become a front runner of transformative molecular therapy. This success is based on fundamental research, which led to the identification of the disease-causing CFTR gene and our subsequent understanding of the disease mechanisms underlying the pathogenesis of cystic fibrosis, working together with a continuously evolving clinical research and drug development pipeline. In this Series paper, we focus on advances since 2018, and remaining knowledge gaps in our understanding of the molecular mechanisms of CFTR dysfunction in the airway epithelium and their links to mucus dysfunction, impaired host defences, airway infection, and chronic inflammation of the lungs of people with cystic fibrosis. We review progress in (and the remaining obstacles to) pharmacological approaches to rescue CFTR function, and novel strategies for improved symptomatic therapies for cystic fibrosis, including how these might be applicable to common lung diseases, such as bronchiectasis and chronic obstructive pulmonary disease. Finally, we discuss the promise of genetic therapies and gene editing approaches to restore CFTR function in the lungs of all patients with cystic fibrosis independent of their CFTR genotype, and the unprecedented opportunities to transform cystic fibrosis from a fatal disease to a treatable and potentially curable one.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Graeber SY, Mall MA. The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches. Lancet. 2023. PMID: 37699417. doi:10.1016/S0140-6736(23)01608-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。